Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab

To find prognostic factors for advanced ovarian cancer patients undergoing first-line therapy with carboplatin, paclitaxel and bevacizumab, we investigated the expression of a disintegrin and metalloprotease 17 (ADAM17) in cancer tissues. ADAM17 has been involved in ovarian cancer development, progression and cell resistance to cisplatin. Tissue microarrays from 309 ovarian cancer patients enrolled in the MITO16A/MANGO-OV2 clinical trial were analyzed by immunohistochemistry for ADAM17 protein expression. Intensity and extent of staining were combined into a semi-quantitative visual grading system (H score) which was related to clinicopathological characteristics of cases and the clinical outcome of patients by univariate and multivariate Cox regression models. ADAM17 immunostaining was detected in most samples, mainly localized in the tumor cells, with variable intensity across the cohort. Kaplan–Meier survival curves, generated according to the best cut-off value for the ADAM17 H score, showed that high ADAM17 expression was associated with worse prognosis for PFS and OS. However, after the application of a shrinkage procedure to adjust for overfitting hazard ratio estimates, the ADAM17 value as prognostic factor was lost. As subgroup analysis suggested that ADAM17 expression could be prognostically relevant in cases with no residual disease at baseline, further studies in this patient category may be worth planning.

[1]  W. Lieb,et al.  ADAM17—A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer , 2021, Cancers.

[2]  S. Pignata,et al.  Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study , 2021, Cancers.

[3]  D. Katsaros,et al.  Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study , 2021, International Journal of Gynecological Cancer.

[4]  S. Sebens,et al.  ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids , 2021, Cancers.

[5]  S. Pignata,et al.  Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience , 2020, Cells.

[6]  Junfa Li,et al.  Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness , 2020, Journal of Neuro-Oncology.

[7]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[8]  D. Longo.  Personalized Medicine for Primary Treatment of Serous Ovarian Cancer. , 2019, The New England journal of medicine.

[9]  A. Marchetti,et al.  Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. , 2019, Critical reviews in oncology/hematology.

[10]  Danielle M. Enserro,et al.  Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Garbers,et al.  The metalloprotease ADAM17 in inflammation and cancer. , 2019, Pathology, research and practice.

[12]  Qiuping Xu,et al.  NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer , 2019, Oncology letters.

[13]  A. Gavin,et al.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.

[14]  Guo-Dong Wang,et al.  ADAM17 promotes cell migration and invasion through the integrin &bgr;1 pathway in hepatocellular carcinoma , 2018, Experimental cell research.

[15]  Ying Chen,et al.  ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1 , 2018, BMC cancer.

[16]  D. Schmidt-Arras,et al.  ADAM17 inhibition enhances platinum efficiency in ovarian cancer , 2018, Oncotarget.

[17]  Ying Chen,et al.  ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma. , 2017, The Journal of surgical research.

[18]  Huirong Shi,et al.  Long non‐coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer , 2017, Experimental cell research.

[19]  A. Skubitz,et al.  Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17 , 2017, The Journal of Biological Chemistry.

[20]  S. Ferrini,et al.  Targeting ADAM17 Sheddase Activity in Cancer. , 2016, Current drug targets.

[21]  G. Mills,et al.  An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors , 2016, Oncogene.

[22]  Jacobus Pfisterer,et al.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.

[23]  M. Swartz,et al.  ADAM17 Promotes Motility, Invasion, and Sprouting of Lymphatic Endothelial Cells , 2015, PloS one.

[24]  X. Zhang,et al.  Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma. , 2015, Genetics and molecular research : GMR.

[25]  A. Bilici,et al.  Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy , 2015, Clinical and Translational Oncology.

[26]  M. Péoc'h,et al.  A novel marker ADAM17 for clear cell renal cell carcinomas: implication for patients' prognosis. , 2014, Urologic oncology.

[27]  Hong-Bin Liu,et al.  A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis , 2014, Molecular medicine reports.

[28]  A. Chalaris,et al.  ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis , 2014, Angiogenesis.

[29]  Ying Chen,et al.  Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers , 2014, BMC Cancer.

[30]  Mingang Ying,et al.  ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma , 2014, Tumor Biology.

[31]  Ji Zhang,et al.  ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival , 2013, Tumor Biology.

[32]  M. Swartz,et al.  ADAM17 Silencing in Mouse Colon Carcinoma Cells: The Effect on Tumoricidal Cytokines and Angiogenesis , 2012, PloS one.

[33]  Zhong-sheng Zhao,et al.  Upregulated Expression of ADAM17 Is a Prognostic Marker for Patients With Gastric Cancer , 2012, Annals of surgery.

[34]  Wei-Guo Zhu,et al.  Prognostic value of ADAM17 in human gastric cancer , 2012, Medical Oncology.

[35]  A. Harris,et al.  The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress , 2012, Oncogene.

[36]  D. Jodrell,et al.  Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo , 2012, PloS one.

[37]  M. Chopp,et al.  ADAM17 promotes glioma cell malignant phenotype , 2012, Molecular carcinogenesis.

[38]  A. Anghel,et al.  Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics. , 2012, Acta histochemica.

[39]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[40]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[41]  Stefan Rose-John,et al.  ADAM17: a molecular switch to control inflammation and tissue regeneration. , 2011, Trends in immunology.

[42]  G. Mills,et al.  Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K. Horiuchi,et al.  Pathological Neovascularization Is Reduced by Inactivation of ADAM17 in Endothelial Cells but Not in Pericytes , 2010, Circulation research.

[44]  M. Gooz.  ADAM-17: the enzyme that does it all , 2010, Critical reviews in biochemistry and molecular biology.

[45]  J. Arribas,et al.  ADAM17 as a therapeutic target in multiple diseases. , 2009, Current pharmaceutical design.

[46]  F. Bolster,et al.  ADAM-17 predicts adverse outcome in patients with breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  J. Bartlett,et al.  Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers. , 2008, American Journal of Clinical Pathology.

[48]  B. LaFleur,et al.  TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer , 2008, Clinical Cancer Research.

[49]  S. Canevari,et al.  The ALCAM Shedding by the Metalloprotease ADAM17/TACE Is Involved in Motility of Ovarian Carcinoma Cells , 2007, Molecular Cancer Research.

[50]  P. Kenny.  TACE: a new target in epidermal growth factor receptor dependent tumors. , 2007, Differentiation; research in biological diversity.

[51]  A. Reeve,et al.  Genome wide expression profiling identifies genes associated with colorectal liver metastasis. , 2007, Oncology reports.

[52]  Satoshi O. Suzuki,et al.  Clinical Significance of Heparin-Binding Epidermal Growth Factor–Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer , 2005, Clinical Cancer Research.

[53]  W. Sauerbrei,et al.  Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint , 2004, Statistics in medicine.

[54]  G. Weskamp,et al.  Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands , 2004, The Journal of cell biology.

[55]  J. Baselga,et al.  TACE is required for the activation of the EGFR by TGF‐α in tumors , 2003 .

[56]  C. Osborne,et al.  Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. , 1988, Cancer research.

[57]  J. Ledermann,et al.  ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology , early and advanced stages , borderline tumours and recurrent disease , 2019 .

[58]  C. Blobel,et al.  ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.

[59]  J. Baselga,et al.  TACE is required for the activation of the EGFR by TGF-alpha in tumors. , 2003, The EMBO journal.

[60]  A. Ullrich,et al.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF , 1999, Nature.